首页> 外文期刊>Analytical and Bioanalytical Chemistry >Urinary excretion profiles of toremifene metabolites by liquid chromatography-mass spectrometry. Towards targeted analysis to relevant metabolites in doping control
【24h】

Urinary excretion profiles of toremifene metabolites by liquid chromatography-mass spectrometry. Towards targeted analysis to relevant metabolites in doping control

机译:液相色谱-质谱联用法测定托瑞米芬代谢产物的尿排泄情况。对兴奋剂控制中相关代谢物进行针对性分析

获取原文
获取原文并翻译 | 示例
           

摘要

In the present study, toremifene urinary excretion studies were evaluated in order to examine main metabolic reactions and to select target metabolites in doping control analysis. Urine samples from three female subjects were collected every 3 h for at least 15 days after the oral administration of a single dose of Fareston® (60 mg). The elemental compositions of the compounds detected were determined by liquid chromatography-mass spectrometry using a time-of-flight system with accurate mass measurement. More detailed structure elucidation was obtained by monitoring the presence or absence of structure-specific ions, using product ion scan and neutral loss acquisition modes, whereas the metabolites urinary profiles were evaluated in selected reaction monitoring acquisition mode. The results showed that the main routes of phase-I modifications involved carboxylation of the chlorinated side chain, N-demethylation and hydroxylation in different positions. Fifteen metabolites were found in all subjects studied, most of them were detected for more than 10 days in the free, glucuronide and sulphate fractions, with a maximum of excretion generally after 9–22 and 34–47 h from drug administration. These metabolites can be divided in two groups: metabolites with the characteristic chlorine isotope pattern and metabolites without the characteristic chlorine isotope pattern. The most abundant and long-term compounds were the carboxylated metabolites followed by the hydroxylated metabolites. Their product ions originating after collision-induced dissociation were observed to occur prevalently in the dimethylaminoethoxy and in the chlorinated side chains. These structure-specific ions were used to design screening and confirmation procedures to positively identify toremifene administration in doping control analysis.
机译:在本研究中,对托瑞米芬的尿排泄研究进行了评估,以检查主要的代谢反应并在掺杂控制分析中选择目标代谢物。口服单剂量(60 mg)后,每3小时至少15天收集一次来自三名女性受试者的尿液样本。使用具有精确质量测量的飞行时间系统,通过液相色谱-质谱法测定检测到的化合物的元素组成。使用产物离子扫描和中性损失采集模式,通过监测结构特异性离子的存在或不存在,可以获得更详细的结构解析,而代谢物的尿谱则以选定的反应监测采集模式进行评估。结果表明,Ⅰ相修饰的主要途径涉及氯化侧链的羧化,N-脱甲基化和不同位置的羟基化。在所有研究对象中发现15种代谢物,其中大多数在游离,葡萄糖醛酸和硫酸盐部分中检测超过10天,通常在给药后9-22和34-47 h排泄最大。这些代谢物可分为两类:具有特征氯同位素特征的代谢物和不具有特征氯同位素特征的代谢物。最丰富和长期的化合物是羧化代谢物,其次是羟化代谢物。观察到它们在碰撞诱导解离后产生的产物离子普遍存在于二甲基氨基乙氧基和氯化侧链中。这些特定于结构的离子被用于设计筛选和确认程序,以在掺杂控制分析中积极鉴定托瑞米芬的给药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号